Please enable JavaScript in your browser. 

Important Announcement

X

DrugPortal is moving to PubChem in December 2022.
Please see the NLM Technical Bulletin article for more information.

Skip to main content
Drug Information Portal National Library of Medicine
Home
 
       Home    Substance
     
1 result for Name/Synonym equals ICLUSIG 
PropertyValue
Drug Name: Ponatinib hydrochloride [USAN] View Structure
Description: A pan-Bcr-Abl protein kinase Inhibitor.

NCI: An orally bioavailable multitargeted receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and antineoplastic activities. Ponatinib hydrochloride inhibits unmutated and all mutated forms of Bcr-Abl, including T315I, the highly drug therapy-resistant missense mutation of Bcr-Abl. This agent also inhibits other tyrosine kinases including those associated with vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs); in addition, it inhibits the tyrosine kinase receptor TIE2 and FMS-related tyrosine kinase receptor-3 (Flt3). RTK inhibition by ponatinib hydrochloride may result in the inhibition of cellular proliferation and angiogenesis and may induce cell death. Bcr-Abl is a fusion tyrosine kinase encoded by the Philadelphia chromosome. (NCI Thesaurus) 
Categories:



 
 
Site Map, Contact Us, Copyright, Privacy, Accessibility
U.S. National Library of Medicine, 8600 Rockville Pike, Bethesda, MD 20894
National Institutes of Health, Health & Human Services
Freedom of Information Act
HHS Vulnerability Disclosure
Drug Information Portal Mobile Site
Last updated: Dec 2022
USA.gov